By Josh White
Date: Monday 16 Sep 2024
(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a clinical-stage firm specialising in stem cell gene correction therapies, on Monday. or login to read the full story
The AIM-traded firm said the collaboration aimed to accelerate the development of cell therapies for genetic diseases, including sickle cell disease (SCD).
Email this article to a friend
or share it with one of these popular networks:
You are here: news